Daniel M Trifiletti1, Clayton Alonso2, Surbhi Grover3, Camilo E Fadul4, Jason P Sheehan5, Timothy N Showalter2. 1. Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia, USA. Electronic address: daniel.trifiletti@gmail.com. 2. Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia, USA. 3. Department of Radiation Oncology, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 4. Department of Neurology, University of Virginia School of Medicine, Charlottesville, Virginia, USA; Department of Neurological Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USA. 5. Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia, USA; Department of Neurological Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Abstract
OBJECTIVE: To analyze the predictors for and clinical impact of gross total resection (GTR) in patients with glioblastoma (GBM). METHODS AND MATERIALS: The National Cancer Database was queried for patients with GBM diagnosed from 2004 to 2013 with known survival and extent of resection. Patients were grouped based on extent of resection into biopsy alone, subtotal resection (STR), and GTR. Univariable analyses and multivariable analyses (MVAs) were performed to investigate factors associated with the likelihood of GTR and overall survival (OS) after diagnosis. RESULTS: A total of 27,865 patients met inclusion criteria. Factors associated with increased odds of GTR on MVA included later year of diagnosis, younger age, higher performance status, nonright-sided tumors, multifocal tumors, and O6-methylguanine-methyltransferase gene promoter non-hypermethylated tumors (each P < 0.020). Factors associated with improved OS on MVA included younger patient age, female sex, race, lower comorbidity score, higher performance score, smaller tumor size, unifocality, O6-methylguanine-methyltransferase hypermethylation, radiotherapy, chemotherapy, and facility volume (each P < 0.005). After we adjusted for each of these factors, compared with biopsy alone, GTR was associated with improved OS (hazard ratio 0.768, P < 0.001), whereas STR (grouped together) was not (hazard ratio 0.995, P = 0.930). CONCLUSIONS: Although a prospective randomized trial on this topic is unlikely to be completed, this large retrospective analysis provides evidence to support the recommendation of GTR in patients with GBM. This study does not support a survival benefit of STR over biopsy alone (when grouped into these 2 groups), although there may be a subset of patients with near total resection who would benefit.
OBJECTIVE: To analyze the predictors for and clinical impact of gross total resection (GTR) in patients with glioblastoma (GBM). METHODS AND MATERIALS: The National Cancer Database was queried for patients with GBM diagnosed from 2004 to 2013 with known survival and extent of resection. Patients were grouped based on extent of resection into biopsy alone, subtotal resection (STR), and GTR. Univariable analyses and multivariable analyses (MVAs) were performed to investigate factors associated with the likelihood of GTR and overall survival (OS) after diagnosis. RESULTS: A total of 27,865 patients met inclusion criteria. Factors associated with increased odds of GTR on MVA included later year of diagnosis, younger age, higher performance status, nonright-sided tumors, multifocal tumors, and O6-methylguanine-methyltransferase gene promoter non-hypermethylated tumors (each P < 0.020). Factors associated with improved OS on MVA included younger patient age, female sex, race, lower comorbidity score, higher performance score, smaller tumor size, unifocality, O6-methylguanine-methyltransferase hypermethylation, radiotherapy, chemotherapy, and facility volume (each P < 0.005). After we adjusted for each of these factors, compared with biopsy alone, GTR was associated with improved OS (hazard ratio 0.768, P < 0.001), whereas STR (grouped together) was not (hazard ratio 0.995, P = 0.930). CONCLUSIONS: Although a prospective randomized trial on this topic is unlikely to be completed, this large retrospective analysis provides evidence to support the recommendation of GTR in patients with GBM. This study does not support a survival benefit of STR over biopsy alone (when grouped into these 2 groups), although there may be a subset of patients with near total resection who would benefit.
Authors: Rameshwar Patil; Anna Galstyan; Tao Sun; Ekaterina S Shatalova; Pramod Butte; Adam N Mamelak; Christine Carico; David S Kittle; Zachary B Grodzinski; Antonella Chiechi; Hui Ding; Keith L Black; Julia Y Ljubimova; Eggehard Holler Journal: Biomaterials Date: 2019-03-23 Impact factor: 12.479
Authors: Christian Lopez Ramos; Michael G Brandel; Jeffrey A Steinberg; Arvin R Wali; Robert C Rennert; David R Santiago-Dieppa; Reith R Sarkar; J Scott Pannell; James D Murphy; Alexander A Khalessi Journal: J Neurooncol Date: 2018-11-20 Impact factor: 4.130
Authors: Cesar A Garcia; Adip G Bhargav; Mieu Brooks; Paola Suárez-Meade; Sujan K Mondal; Natanael Zarco; Karim ReFaey; Mark Jentoft; Erik H Middlebrooks; Matija Snuderl; Anna Carrano; Hugo Guerrero-Cazares; Paula Schiapparelli; Rachel Sarabia-Estrada; Alfredo Quiñones-Hinojosa Journal: Mol Cancer Ther Date: 2021-08-31 Impact factor: 6.009
Authors: Peter Abraham; Reith Sarkar; Michael G Brandel; Arvin R Wali; Robert C Rennert; Christian Lopez Ramos; Jennifer Padwal; Jeffrey A Steinberg; David R Santiago-Dieppa; Vincent Cheung; J Scott Pannell; James D Murphy; Alexander A Khalessi Journal: Radiology Date: 2019-03-26 Impact factor: 29.146